ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for...
18 insider purchases on record · latest filing 2025-04-24.
Insiders have also filed 56 sale transactions at PROK.